Why are MRI biomarkers underused in Parkinson's disease clinical trials?

Despite their clear scientific value, MRI biomarkers are used as primary, secondary, or exploratory outcomes in only approximately 16% of active Parkinson's disease clinical trials. The underuse reflects several barriers: the analytical complexity of advanced MRI sequences, the logistical challenges of standardising data collection across multiple sites and scanner vendors, and the historical reliance on clinical scales such as UPDRS as the dominant outcome measures. As MRI acquisition protocols become more standardised and cloud-based imaging platforms reduce the logistical burden, MRI biomarkers are increasingly accessible for broader trial deployment.

What does FDA guidance say about imaging biomarkers as clinical trial endpoints?

The FDA has released specific guidance to assist and support the use of imaging data in clinical trials as primary or component endpoints. This guidance acknowledges that imaging biomarkers can provide objective, reproducible, and quantifiable evidence of treatment effects — qualities that are difficult to achieve with traditional clinical rating scales. By incorporating FDA-endorsed imaging endpoints, Parkinson's trial sponsors can align their evidence packages with regulatory expectations and potentially accelerate the pathway to approval.

How can MRI biomarkers improve patient stratification in Parkinson's disease trials?

Parkinson's disease is a heterogeneous condition comprising diverse clinical phenotypes and atypical parkinsonian syndromes with overlapping features. MRI biomarkers — including quantitative susceptibility mapping (QSM) for iron deposition in the substantia nigra, free-water diffusion tensor imaging (DTI) for white matter microstructure, and neuromelanin-sensitive MRI — can distinguish between PD subtypes and predict response to specific therapies. Improved patient stratification enhances statistical power, meaning trials can achieve meaningful results with smaller sample sizes and lower overall cost. Any reduction in the misclassification of patients entering a trial directly reduces the risk of Phase 2 to Phase 3 transition failure.

What is the Michael J. Fox Foundation's Imaging Program and why is it relevant?

The Michael J. Fox Foundation's Biomarker Advancement Programs include a dedicated Imaging Program that specifically targets imaging-based solutions to accelerate Parkinson's disease drug development. The program reflects the foundation's recognition that the limited transition of disease-modifying therapies from Phase 2 to Phase 3 may stem in part from an incomplete understanding of PD biology — a gap that in vivo imaging biomarkers are well-positioned to fill. The program's existence signals strong institutional and philanthropic support for imaging-first approaches in PD research, which is an encouraging indicator for sponsors considering MRI biomarker investment.

How can existing MRI data be repurposed to maximise study value in Parkinson's research?

Parkinson's disease trials often collect MRI data primarily for safety monitoring, leaving a wealth of high-quality imaging data underanalysed. As MRI acquisition protocols become increasingly standardised and AI-powered analysis tools mature, sponsors can retrospectively apply advanced analytical algorithms to previously collected datasets — extracting new biomarker insights without the cost of a new study. This retrospective approach is especially valuable given the growing availability of large longitudinal imaging datasets and the rapidly improving capabilities of AI algorithms for tasks such as volumetric analysis, iron quantification, and white matter microstructure assessment.

What infrastructure does QMENTA provide for MRI biomarker studies in Parkinson's disease?

QMENTA provides a cloud-native imaging platform that addresses the operational challenges of multi-site MRI biomarker studies in Parkinson's disease: centralised data management with automated protocol adherence checking and quality control, a catalogue of validated AI imaging biomarker algorithms (including those applicable to Parkinson's disease such as volumetric analysis and quantitative MRI tools), regulatory-ready audit trails and documentation, and flexible integration with other imaging endpoints. The platform is designed to be deployable without site-level software installation, reducing the burden on clinical sites and accelerating study start-up timelines.

What is the Michael J. Fox Foundation's Imaging Program?

The Michael J. Fox Foundation's Biomarker Advancement Programs include a dedicated Imaging Program targeting imaging-based solutions to accelerate Parkinson's disease drug development. The program reflects recognition that the limited Phase 2 to Phase 3 transition of disease-modifying therapies may stem from an incomplete understanding of PD biology — a gap that in vivo imaging biomarkers are well-positioned to fill.

Research use

QMENTA vs. Medidata: Choosing the Right Imaging Platform for Clinical Trials

QMENTA vs Medidata Rave Imaging: compare AI biomarkers, central review, imaging EDC, and which platform fits your clinical trial.

Imaging Team

Apr 13, 2026

Research use Clinical Trials Neuroimaging AI

QMENTA is a purpose-built medical imaging platform for clinical trials, with a strong focus on AI-powered neuroimaging and quantitative biomarkers. Medidata Rave Imaging is a clinical imaging module within the broader Medidata Unified Platform, which also includes Rave EDC and other eClinical products. Sponsors running imaging-centric studies, particularly in neurology, oncology, or rare disease, often find QMENTA delivers deeper imaging capabilities. Organizations already standardized on Medidata typically value Rave Imaging's tight integration with Rave EDC and the rest of the Medidata suite.

What Is QMENTA?

QMENTA was founded in 2013 and is headquartered in Boston, with an office in Barcelona. The company's platform received FDA 510(k) clearance as an AI-enabled imaging management and analysis solution used in both clinical research and clinical care settings.

The core product, the QMENTA Imaging Hub, combines five integrated components in a single system:

Imaging Cloud
Smart Uploader
AI Imaging Biomarkers (50+ algorithms)
Central Review with adjudication tools
Imaging EDC with query management and reporting

The company originated in neuroscience and applies its platform across multiple sclerosis, Alzheimer's disease, Parkinson's disease, ALS, rare pediatric disorders, and oncology. Research and biopharma collaborators have included Massachusetts General Hospital and Alzamend Neuro, among others.

What Is Medidata Rave Imaging?

Medidata is a Dassault Systemes company and a broad eClinical platform provider. Its product suite includes Rave EDC, eCOA, eConsent, RTSM, Sensor Cloud, and imaging management.

Rave Imaging is the imaging management module within the Medidata Unified Platform, sitting alongside Rave EDC as part of a unified clinical data environment.

Key capabilities include:

Configurable workflow management for image submission, de-identification, and distribution
Automated edit checks during image upload
Centralized image collection and archiving across sites and core labs
AI tools for pixel PHI detection, image quality checks, and lesion identification
21 CFR Part 11-compliant data management throughout

Rave Imaging has been deployed in over 1,000 imaging studies and processes more than 100 million images per year across a network of more than 21,000 sites and 75 core labs. It is particularly attractive to sponsors that already run core clinical data operations on the Medidata platform.

How Do QMENTA and Medidata Differ in Their Approach to Imaging?

QMENTA: Imaging is the entire platform, not a feature. Every component, from data ingestion and multi-site QC through AI biomarker analysis, central review, and an imaging-specific EDC, is built around imaging data and workflows. Scientific expertise from neuroscientists, radiologists, and imaging scientists is embedded into implementation and ongoing trial support.

Medidata Rave Imaging: Imaging is one module within a larger unified eClinical environment that centers on Rave EDC. The main value is seamless data flow between Rave Imaging, Rave EDC, and other Rave modules, plus standardized workflows across large sponsor portfolios.

Practical implications for trial operations leaders: Teams running imaging-primary or biomarker-heavy studies, such as those with neuroimaging endpoints, tumor response criteria, or rare disease biomarker validation, tend to prioritize QMENTA's depth in imaging science and analytics. Teams where imaging is one of many parallel data streams that need to be collected may prioritize Medidata's unified ecosystem, particularly if their organization already has an enterprise agreement across multiple Medidata products.

Side-by-Side Comparison: QMENTA vs. Medidata Rave Imaging

Dimension	QMENTA	Medidata Rave Imaging
Platform type	Imaging-specialist platform for clinical and research imaging workflows	Imaging management module within a broader Medidata eClinical suite
AI biomarkers and tools	50+ validated AI imaging biomarkers and algorithms, especially in neurology, with a curated catalog and partner marketplace	AI for pixel PHI detection, image quality checks, and lesion identification to support workflow automation
Regulatory posture	FDA 510(k)-cleared for AI-powered imaging management and analysis; supports 21 CFR Part 11-compliant use in trials	21 CFR Part 11-compliant clinical data management and imaging system within the Medidata platform
Central review	Native central review with adjudication tools and access to specialist radiologist networks	Central reading within Rave Imaging, with measurement capture and image archival integrated into Medidata workflows
EDC	Purpose-built Imaging EDC for imaging data and queries; integrates with third-party EDC systems via open APIs	Rave EDC is a separate but tightly unified module, often used as the core EDC across a sponsor's full portfolio
Core expertise	Neuroimaging, rare diseases, and quantitative imaging biomarkers, with scientific advisory involvement	Broad eClinical operations and data management; imaging is one module within a large product suite
Best fit	Imaging-centric trials in neuro, oncology, rare disease, or biomarker-driven programs requiring deep AI imaging analytics	Sponsors already invested in the Medidata Unified Platform who want imaging tightly tied to Rave EDC and other Rave products
Scale and ecosystem	Used across multi-site trials and collaborations with global research institutions; focused on imaging-intensive programs	Deployed across 21,000+ sites and 75+ core labs worldwide as part of Medidata's clinical cloud
Deployment	Cloud-based, zero-footprint viewer accessible via browser to reduce site IT burden	Cloud-based, part of the Medidata clinical cloud with single sign-on and unified access for Rave users

Which Platform Is Better for Neuroimaging Trials?

QMENTA was founded with a neuroscience focus, and its biomarker catalog is heavily weighted toward neurological disease areas, including multiple sclerosis, Alzheimer's disease, Parkinson's disease, and other neurodegenerative and rare conditions. The platform covers the full neuroimaging workflow, from multi-site data harmonization and QC through AI biomarker analysis and central read, within a single imaging environment. Academic medical centers and biopharma partners have selected QMENTA for neuroimaging-heavy trials and research programs because of this scientific depth.

Medidata Rave Imaging can support neuroimaging studies as part of broader trial operations, mostly as a data lake, but it does not emphasize disease-specific neuroimaging biomarker libraries or dedicated neuroscience advisory support to the same degree.

What Are the Operational Considerations for Clinical Trial Leaders?

Site burden: QMENTA's cloud-based, zero-footprint viewer is designed to minimize local installation and configuration at imaging sites, which can simplify onboarding for imaging centers. Medidata benefits from existing site familiarity where sites already use Rave EDC and related modules, consolidating logins and workflows into a single environment.

Study setup: QMENTA includes imaging study design and site configuration support as part of its service model, with specialist input on imaging endpoints and QC protocols. Medidata offers professional services for configuring Rave Imaging and aligning it with Rave EDC and other modules.

Compliance and validation: Both platforms support 21 CFR Part 11-compliant use in clinical trials. QMENTA's FDA 510(k) clearance is relevant for sponsors who want AI-enabled imaging workflows operating under a regulated medical device framework.

Commercial model and support: Medidata is typically positioned as an enterprise-scale subscription across multiple products. QMENTA's engagement model is designed to scale across the full spectrum of sponsors from academic labs and single-study biotechs to large biopharma running multi-trial, multi-site programs. Both vendors provide enterprise-grade technical support; QMENTA additionally emphasizes access to imaging scientists and clinicians for complex trial design and execution questions.

Frequently Asked Questions

Can QMENTA integrate with Medidata Rave EDC?

Yes. QMENTA exposes open APIs so sponsors can integrate imaging data and queries with external EDC systems, including Medidata Rave. This allows QMENTA to function as the imaging hub while Rave EDC remains the system of record for non-imaging clinical data.

Is QMENTA FDA-approved?

QMENTA's platform has received FDA 510(k) clearance as an AI-enabled imaging management and analysis solution. This means the agency reviewed and authorized its use as medical device software within the cleared indications. Medidata Rave Imaging is designed and validated as a 21 CFR Part 11-compliant clinical data and imaging management system rather than as a 510(k)-cleared medical device.

Which platform is better for multi-site trials with imaging endpoints?

For trials where imaging endpoints are primary and scientifically complex, QMENTA's multi-site harmonization tools, centralized QC, and AI biomarker catalog are built for imaging-first operations. For large portfolios where imaging is one of many data streams and the organization already runs Rave EDC and other Medidata modules, Rave Imaging's tight integration and standardized workflows across thousands of sites can be a strong fit.

Does Medidata have AI imaging biomarkers comparable to QMENTA?

Medidata focuses its imaging AI on workflow-oriented capabilities: pixel PHI detection, de-identification, and lesion detection to support radiologists and reduce variability. QMENTA provides a catalog of over 50 AI imaging biomarkers and algorithms, concentrated in neurology and related indications, and hosts additional algorithms from external scientific partners through a marketplace.

What therapeutic areas does QMENTA support beyond neurology?

QMENTA originated in neuroscience but has expanded its imaging capabilities to cover oncology and rare diseases, including conditions such as adrenoleukodystrophy (ALD) and Rett Syndrome. Medidata Rave Imaging is designed as a general-purpose imaging management system and is not oriented toward a specific therapeutic area.

Summary: How to Choose Between QMENTA and Medidata

Choose QMENTA if...

Imaging is the primary endpoint or core scientific driver of your trial
You need advanced AI biomarkers, especially in neurology or rare disease
You want a 510(k)-cleared imaging platform with embedded scientific expertise
You are running a standalone imaging program or need an open-API imaging hub that plugs into your existing EDC

Choose Medidata Rave Imaging if...

Your organization already runs end-to-end trial operations on the Medidata Unified Platform
Imaging is one data stream among many and you want a single vendor for EDC, eCOA, RTSM, and imaging
Your site network is already familiar with the Rave environment
Enterprise-scale standardization across a large trial portfolio is a priority

Have questions about how QMENTA fits your protocol and imaging data flow? Visit qmenta.com/contact to schedule a 30-minute technical demonstration with QMENTA's imaging specialists.